title: Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
authors.forename: A M M
authors.initials: AM
authors.lastname: Eggermont
authors.forename: V
authors.initials: V
authors.lastname: Chiarion-Sileni
authors.forename: J-J
authors.initials: JJ
authors.lastname: Grob